Pfizer Invites Retail Shareholders to a General Q&A Session
May 4, 2023
NEW YORK, May 4, 2023 — Pfizer Inc. (NYSE: PFE) announced today that its retail shareholders are invited to submit questions for the first general Q&A session on the Say Technologies platform, a new way for investors to communicate with Pfizer. Christopher Stevo, Chief Investor Relations Officer will provide written answers to a selection of questions from registered retail shareholders beginning on May 10th at 4:00 p.m. U.S. Eastern Daylight Time (EDT).
Starting today through May 9th, registered retail shareholders can submit and upvote questions on the Q&A platform. Retail shareholders are welcome to submit questions to management on topics including Pfizer’s corporate strategy, innovation pipeline, environmental, social and governance (ESG) programs, and recent financial results.
To submit questions, please visit and register here. The Q&A platform will remain open until 24 hours before written answers begin on May 10th.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at pfizer.com. In addition, to learn more, please visit us on pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The Q&A session may include forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics and size, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities; and our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our ongoing efforts to respond to COVID-19, including our COVID-19 products; our expectations regarding the impact of COVID-19 on our business, operations and financial results; our Environmental, Social and Governance (ESG) priorities, strategy and goals; and other statements about our business, operations and financial results, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at sec.gov and pfizer.com.
The forward-looking statements in the Q&A session speak only as of the original date of the Q&A session. Pfizer assumes no obligation to update forward-looking statements contained in the Q&A session as the result of new information or future events or developments.